Medication Adherence With Telehealthcare Medication Therapy Management
MATCH
Improving Medication Adherence With Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults With Asthma
3 other identifiers
interventional
321
1 country
21
Brief Summary
Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma (MATCH) is a multi-center, randomized parallel group study targeted to an at-risk population of Adolescents and Young Adults (AYA) with uncontrolled asthma who have poor adherence with prescribed Inhaled corticosteroid (ICS) therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2019
Longer than P75 for not_applicable
21 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 5, 2019
CompletedFirst Posted
Study publicly available on registry
June 7, 2019
CompletedStudy Start
First participant enrolled
November 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 14, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedJanuary 15, 2026
January 1, 2026
5.3 years
June 5, 2019
January 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Time (days) to first exacerbation event
Time to first asthma exacerbation is the time to first exacerbation event defined as a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, or asthma-specific emergency department visit with treatment with systemic corticosteroids, or asthma-specific hospitalization, or death (all cause and asthma exacerbation). 104. These data will be collected by self-report in the "My Asthma" bi-weekly assessment questionnaire, and verified by the study site coordinator with the participant's provider.
12 months
Proportion of adherent days as assessed by Propeller sensors
Adherence will be measured using data collected from Propeller sensors. Adherence for each day is calculated as the number of inhalations taken divided by the expected number of doses. A day will be defined as adherent if the participant completes 80% or more of the prescribed inhalations. The primary outcome will be the proportion of adherent days over the course of follow-up, i.e. from the randomization visit to the 1-year visit.
12 months
Study Arms (2)
MTM-EAM
EXPERIMENTALMedication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management \[MTM-EAM\]
EAM only
ACTIVE COMPARATORElectronic Adherence Self-Management \[EAM\] only
Interventions
MTM is an individualized approach to "optimize medication use for improved patient outcomes" and is designed to "empower patients to take an active role in managing patients' medications" thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up
Participants will have a sensor which monitors their adherence to medication use
Eligibility Criteria
You may qualify if:
- Age 12 through 35 years
- Speaks English or Spanish
- Physician diagnosed asthma (without any other co-morbid pulmonary disease)
- Prescribed ICS treatment for at least 3 months prior to screening
- Adherence to Refills and Medication Scale (ARMS) 7-item questionnaire score of \>8 (low or moderate adherence)
- Current use of albuterol metered dose inhaler (MDI) for rescue: ProAir, Ventolin, albuterol sulfate (from Prasco or Teva)
- Uncontrolled asthma:
- Symptomatic asthma defined as 3 of the following in the past 4 weeks:
- Daytime symptoms of asthma more than twice per week
- Any night awakening due to asthma
- Rescue inhaler use for symptoms more than twice per week
- Any activity limitation due to asthma; OR
- Asthma Control Test score ≤19
- Has iPhone or Android smart phone with Short Message Service (SMS)
- Has access to reliable WiFi service and a device with capability for telemedicine study visits
- +2 more criteria
You may not qualify if:
- Use of an investigational treatment in the previous 30 days.
- Previous enrollment in MATCH Structured Interviews ( Aim 1)
- Currently enrolled in an intervention trial
- Currently uses an ICS not compatible with the Propeller sensor
- Inability to comply with study procedures, including:
- Inability or unwillingness to provide informed consent (or assent in the case of a minor).
- Inability to perform study measurements.
- inability to be contacted by phone via calls and /or text messaging
- Not willing to have video chat
- Any condition(s) in the opinion of the physician that puts the participant at risk from participating in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)collaborator
- Johns Hopkins Universitylead
- Nemours Children's Health Systemcollaborator
- American Lung Associationcollaborator
Study Sites (21)
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
University of Arizona
Tucson, Arizona, 85724, United States
University of California at San Francisco
San Francisco, California, 94143, United States
National Jewish Medical and Research Center
Denver, Colorado, 80206, United States
Nemours Children's Specialty Care
Jacksonville, Florida, 32207, United States
University of Florida College of Medicine
Jacksonville, Florida, 32209, United States
University of Illinois at Chicago
Chicago, Illinois, 60608, United States
Northwestern University
Chicago, Illinois, 60611, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
University of Chicago Hospitals
Chicago, Illinois, 60637, United States
University of Kansas Medical Center
Kansas City, Kansas, 66103, United States
University of Michigan
Ann Arbor, Michigan, 48109-5360, United States
Children's Mercy Hospital
Kansas City, Missouri, 64108, United States
New York University School of Medicine
New York, New York, 10016, United States
Columbia University Medical Center
New York, New York, 10029, United States
Mount Sinai National Jewish Health Respiratory Institute; Icahn School of Medicine
New York, New York, 10029, United States
Duke University Medical Center
Durham, North Carolina, 27710, United States
Temple University
Philadelphia, Pennsylvania, 19140, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
Vermont Lung Center at The University of Vermont
Colchester, Vermont, 05466, United States
Pacific Northwest Airways - VA Puget Sound Healthcare System
Seattle, Washington, 98108, United States
Related Publications (1)
Blake KV. Telemedicine and adherence monitoring in children with asthma. Curr Opin Pulm Med. 2021 Jan;27(1):37-44. doi: 10.1097/MCP.0000000000000739.
PMID: 33105234DERIVED
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kathryn Blake, Pharm.D
Nemours Children's Specialty Care
- PRINCIPAL INVESTIGATOR
Robert Wise, MD
Johns Hopkins School of Medicine
- PRINCIPAL INVESTIGATOR
Janet Holbrook, PhD
Johns Hopkins Bloomberg School of Public Health
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 5, 2019
First Posted
June 7, 2019
Study Start
November 18, 2019
Primary Completion
March 14, 2025
Study Completion
June 30, 2025
Last Updated
January 15, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share